drugset / Trial / NCT06176261

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

NCT06176261

Phase 2 Recruiting 58 enrolled Sarah Sammons, MD Daiichi Sankyo · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)

Timeline

Start
2024-01-08
Primary completion
2028-01-01
Completion
2029-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Datopotamab deruxtecan Monoclonal antibody Intravenous